$1.21
2.42% day before yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US75989R1077
Symbol
RNXT

RenovoRx Inc Stock price

$1.21
-0.06 4.72% 1M
-0.16 11.68% 6M
-0.08 6.20% YTD
-0.02 1.63% 1Y
-0.74 37.79% 3Y
-6.05 83.33% 5Y
-6.05 83.33% 10Y
-6.05 83.33% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.03 2.42%
ISIN
US75989R1077
Symbol
RNXT
Industry

Key metrics

Basic
Market capitalization
$44.3m
Enterprise Value
$29.7m
Net debt
positive
Cash
$14.6m
Shares outstanding
36.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
184.4 | 32.1
EV/Sales
123.6 | 21.5
EV/FCF
negative
P/B
3.4
Financial Health
Equity Ratio
55.2%
Return on Equity
-196.8%
ROCE
-81.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$240.0k | $1.4m
EBITDA
$-11.6m | -
EBIT
$-11.6m | $-7.8m
Net Income
$-10.2m | $-12.1m
Free Cash Flow
$-10.3m
Growth (TTM | estimate)
Revenue
- | 3,345.0%
EBITDA
- | -
EBIT
-9.3% | 29.4%
Net Income
-26.2% | -37.6%
Free Cash Flow
-5.9%
Margin (TTM | estimate)
Gross
60.8%
EBITDA
-4,834.6% | -
EBIT
-4,835.0%
Net
-4,232.5% | -879.3%
Free Cash Flow
-4,298.3%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
0.3%
Employees
10
Rev per Employee
$0.0
Show more

Is RenovoRx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

RenovoRx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a RenovoRx Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a RenovoRx Inc forecast:

Buy
90%
Hold
10%

Financial data from RenovoRx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.24 0.24
-
100%
- Direct Costs 0.09 0.09
-
38%
0.15 0.15
-
63%
- Selling and Administrative Expenses 5.34 5.34
6% 6%
2,225%
- Research and Development Expense 6.41 6.41
15% 15%
2,671%
-12 -12
-
-4,833%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
9% 9%
-4,835%
Net Profit -10 -10
26% 26%
-4,233%

In millions USD.

Don't miss a Thing! We will send you all news about RenovoRx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RenovoRx Inc Stock News

Neutral
Business Wire
6 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461). The initiation of this study demonstrates RenovoRx's comm...
Neutral
Business Wire
20 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced it will host its second quarter 2025 financial results and business highlights conference call on August 14, 2025, at 4:30 p.m. ET...
Neutral
Seeking Alpha
3 months ago
RenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald Kocak - VP Controller and Principal Accounting Officer Conference Call Participants Rafay Khalid - Ascendiant Capital Markets Operator Good afternoon, everyone, and welcome to the RenovoRx Q1 2025 F...
More RenovoRx Inc News

Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. Its therapy platform, RenovoRx, handles the optimizing drug concentration in solid tumors using approved small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Los Altos, CA.

Head office United States
CEO Shaun Bagai
Employees 10
Founded 2009
Website renovorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today